Mesoblast Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin and Not Subject to U.S. Tariffs
April 03, 2025 18:58 ET | Source: Mesoblast Limited NEW YORK, April…
Mesoblast Added to S&P/ASX 200 INDEX
March 06, 2025 18:54 ET | Source: Mesoblast Limited NEW YORK, March…
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
--- The United States FDA Approves the Initiation for Phase II Efficacy…
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease…
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of…
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3…
Abivax Announces a Change to the Composition of its Board of Directors
Abivax Announces a Change to the Composition of its Board of Directors…
GEn1E Lifesciences appoints Franois Nader, MD as Chair of its Board of Directors
Former CEO of NPS Pharma brings strong biotech expertise to further accelerate…
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc,…
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19,…